21/09/2026 18:00
SOCIETE ANONYME D' EXPLOSIFS ET DE PRODUITS CHIMIQUES : Oddo BHF initiates coverage of EPC Groupe
pstrongEPC Groupe Euronext EXPL announces initiation of equity research coverage by Oddo BHF/strong/p pIn its research report entitled “emAll Catalysts Are Green/em”, dated September 16, 2026, Oddo BHF initiated coverage of EPC Groupe's shares under a sponsored research... Lire...
21/09/2026 17:45
EQS-Adhoc: Airbus reports share buyback transactions 11-18 September 2026 
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd pEQSAdhoc: Airbus SE / Key words: Share Buybackbr/ Airbus reports share buyback transactions 1118 September 2026  br/br/ 21Sep2026 / 17:45 CET/CESTbr/ Disclosure of an inside information acc. to... Lire...
21/09/2026 17:45
Charwood Energy : Charwood Energy continues to grow at a strong pace. H1 revenue up +43% to €5.6m.
html xmlns=http://www.w3.org/1999/xhtmlbody table border= cellpadding= cellspacing=trtd pCharwood Energybr/ Charwood Energy continues to grow at a strong pace. H1 revenue up 43% to €5.6m. br/br/span21Sep2026 / 17:45 CET/CEST/spanbr/ Dissemination of a... Lire...
21/09/2026 17:45
STREAM WIDE : POSITIVE H1 2026 RESULTS - CONTINUED INVESTMENT TO DRIVE FUTURE GROWTH
p align=center class=actbigH1 2026 REVENUE: strong€12.8 million €1.3 m/strong/p p align=center class=actbigEBITDA: strong€6.3 million €0.1 m/strong/p p align=center class=actbigEBIT: strong€1.7 million €0.9 m/strong/p p align=center class=actbigNET INCOME:... Lire...
21/09/2026 17:45
LUMIBIRD: 2026 first-half results: photonics strong growth and improved profitability
p align=rightLannion, 21/09/2026 – 5:45 pm/p pstrong2026 FIRSTHALF RESULTS: PHOTONICS STRONG GROWTH AND IMPROVED PROFITABILITY/strong/p ul listrongGroup revenue up 7.4% 9.7% on a likeforlike basis/strong/li listrongPhotonics Division: revenue up 15.3% and EBITDA up... Lire...
21/09/2026 17:40
2026 First Half Results: Strong Growth in Revenue, Profitability and Operating Free Cash Flow Full-year guidance confirmed
ul listrongRevenue of €820m in IFRS 34% and of €839m on an adjustedsupa href=#_ftn1 name=_ftnref1strong[1]/strong/a/sup basis 29% and up 37% at constant exchange rates and tariffs/strong/li listrongVASsupa href=#_ftn2 name=_ftnref2strong[2]/strong/a/sup revenue... Lire...
21/09/2026 17:00
EQS-News: Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Menarini Industrie Farmaceutiche Riunite / Key words: Miscellaneous/Miscellaneous br/ Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo®... Lire...